Atopic dermatitis (AD) is a chronic disease that affects an increasing number of children and adults. The skin is dry and ...
A cohort study finds the risk for acne in patients on JAK inhibitors for atopic dermatitis was about 2.5 times greater than ...
InvestorsHub on MSN
Corvus Pharmaceuticals shares jump on encouraging atopic dermatitis trial results
Corvus Pharmaceuticals (NASDAQ:CRVS) shares surged 48% on Tuesday after the company released positive findings from a Phase 1 ...
If you’re a person of color, finding the right treatment for atopic dermatitis, a common form of eczema, can be challenging. Even though the disease is more prevalent in Black Americans than white ...
Experts discuss the unique challenges of managing atopic dermatitis (AD) in pediatric and adolescent patients, emphasizing the strategic use of topical treatments to improve adherence, reduce ...
Nearly 9 in 10 adults and parents of children with plaque psoriasis, atopic dermatitis, and seborrheic dermatitis being ...
TRex Bio banked a Series B extension to advance its atopic dermatitis program, which is competing in a crowded field.
The ADHAND trial has demonstrated that tralokinumab significantly improved skin clarity, itch, and pain in adults with moderate-to-severe hand atopic dermatitis. All primary and secondary ...
How do dermatologists diagnose atopic dermatitis? To diagnose atopic dermatitis, also called eczema, a board-certified dermatologist carefully examines your (or your child's) skin and asks questions. ...
Zacks Investment Research on MSN
Corvus Pharmaceuticals stock rallies 209% in a month: Here's why
Shares of Corvus Pharmaceuticals CRVS have skyrocketed 208.8% in a month. The massive stock price rally was observed after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results